ArticleCancers2021

Oral Metronomic Maintenance Therapy Can Improve Survival in High-Risk Neuroblastoma Patients Not Treated with ASCT or Anti-GD2 Antibodies.

Xiaofei Sun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.